Skip to content

Contribution Of Nuclear Magnetic Resonance Imaging In The Study Of Diabetic Cardiomyopathy

Contribution Of Nuclear Magnetic Resonance Imaging In The Study Of Diabetic Cardiomyopathy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01295385
Enrollment
25
Registered
2011-02-14
Start date
2011-02-28
Completion date
2015-06-30
Last updated
2015-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiomyopathy, Diabetic

Keywords

type 2 diabetes, Cardiovascular diseases, coronary syndrome have abnormalities of glucidic metabolism

Brief summary

Diagnosis of diabetic cardiomyopathy is then retained, supposing a change in the coronary microcirculation linked to an endothelial dysfunction. Abnormalities of the myocardial metabolism is frequently associated. It is regrettably about a hypothesis difficult to verify with current medical techniques.This deficiency being not only harmful to the diagnosis, but also to the assessment of the efficiency of the medical treatment on the myocardial metabolism and the endothelial function. Techniques of nuclear magnetic resonance offer interesting perspectives.

Detailed description

These techniques allow in this context: 1. to quantify the myocardial blood flow at rest and after cold pressor test in a population of healthy volunteers. The myocardial blood flow will be obtained by estimating myocardial blood flow at the venous coronary sinus site. This allows us to quantify a possible endothelial dysfunction in a reproducible way. No MRI study in diabetic patients has ever been led until now with this technique. 2. to estimate the metabolic and structural abnormalities in this population, with particularly: * Quantification of the myocardial metabolism in vivo by spectrometry of phosphorus 31. * Structural abnormalities: become integrated into the description of diabetic cardiomyopathy.

Interventions

OTHERNUCLEAR MAGNETIC RESONANCE IMAGING

Techniques of nuclear magnetic resonance offer interesting perspectives in this context, and particularly to quantify the myocardial blood flow at rest and after cold pressor test in a population of healthy volunteers.

Sponsors

Assistance Publique Hopitaux De Marseille
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* more than 18 years old * patient type 2 diabetes affects taken care more than 5 years to Timone Hospital * patient with a diabetic cardiomyopathy * informed and consented

Exclusion criteria

* less than 18 years * Pregnant woman * patient type 1 diabetes affects * patient presents a cardiomyopathy mixed (no diabetic) * patients presents an arrhythmia ventriculaire or above - ventriculaire * Unstable hémodynamique patients

Design outcomes

Primary

MeasureTime frameDescription
To quantify the myocardial blood flow at rest and after cold pressor test in a population of healthy volunteers12 monthsThe myocardial blood flow will be obtained by estimating myocardial blood flow at the venous coronary sinus site. This allows us to quantify a possible endothelial dysfunction in a reproducible way. No MRI study in diabetic patients has ever been led until now with this technique.

Secondary

MeasureTime frameDescription
To estimate the metabolic and structural abnormalities in this population12 months* Quantification of the myocardial metabolism in vivo by spectrometry of phosphorus 31 which allows to estimate the energy state of the heart by analyzing the phosphorous metabolites with high energy involved in the myocardial energetic metabolism. * Structural abnormalities: evaluation of the fibrosis and the collagenic deposits by T1 mapping and measurement of relaxation T2 as well as the study of the late enhancement of gadolinium. These structural abnormalities become integrated into the description of diabetic cardiomyopathy.

Countries

France

Contacts

Primary ContactJacques Quilici, Doctor
jacques.quilici@ap-hm.fr+33491385973

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026